TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02222740
Drug: 20 mg of Hydrocodone Bitartrate Extended Release (HC-ER)
Normalized name: hydrocodone
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Schedule II Class
Study: NCT01365052
Drug: Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules each containing naproxen sodium 220 mg /diphenhydramine hydrochloride (DPH) 25 mg are taken orally with a full glass of water approximately 30 minutes prior to bedtime for 10 consecutive days
Study: NCT01365052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo capsules are taken orally with a full glass of water 30 minutes prior to bedtime for 10 consecutive days
Study: NCT00424983
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00796822
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One pill three times a day for 8 weeks
Study: NCT02126865
Drug: Placebo to BI 1060469
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT02126865
Drug: BI 1060469 Healthy
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT01582347
Drug: Subutex®/Suboxone®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to the Subutex®/Suboxone® treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In, Transfer, and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In and Transition Periods.~Sublingual Subutex® tablets containing 8 mg buprenorphine and and sublingual Suboxone® tablets containing 8 mg buprenorphine and 2 mg naloxone.
Study: NCT01582347
Drug: Placebo for RBP-6300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to the Subutex®/Suboxone® treatment arm take Placebo for RBP-6300 during the Transfer and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take Placebo for RBP-6300 during the Transition Period.
Study: NCT01582347
Drug: Placebo for Subutex®/Suboxone®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to the RBP-6300 treatment arm take Placebo for Subutex®/Suboxone® during the Transfer Period.
Study: NCT01426126
Drug: Genexol PM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genexol-PM at a dose of 240 mg/㎡ was diluted in 500 ml of 5% dextrose solution and infused i.v. for 3 hours on day 1. Specialized i.v. infusion sets or in-line filter was not required for the administration. The dose of Genexol-PM was escalated to 300 mg/㎡ from the second cycle when pre-specified criteria were fulfilled (nadir ANC ≥ 1,000/ mm3, nadir platelet count ≥ 100,000/ mm3, and no grade 2 or worse non-hematologic toxicities with the exception of alopecia)
Study: NCT02968485
Drug: SHR7390
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg and 0.5 mg. Multiple tablets of SHR7390 will be administered daily to achieve targeted doses of SHR7390: 0.25 mg-4 mg. Tablets will be orally administered with 240 ml water, once daily, 2 hours after a meal.
Study: NCT00417209
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered orally from Day 1 to Day 14 q3w
Study: NCT00766688
Drug: AVE5530
Approvals — FDA: no, EMA: no, PMDA: no
Description: * one tablet in the evening with dinner~* in addition to high doses of statin treatment
Study: NCT02750293
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00766688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * one tablet in the evening with dinner~* in addition to high doses of statin treatment
Study: NCT00845858
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 minutes before meals and at bedtime
Study: NCT01484275
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
Study: NCT01809106
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 microg/h
Study: NCT00508365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules to match each dose level will be provided.
Study: NCT01124396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005044
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist of choice. The manufacturer's instructions should be followed.
Study: NCT04168346
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% infusion
Study: NCT02381886
Drug: IDH305
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00094302
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.
Study: NCT00094302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of spironolactone
Study: NCT04226443
Drug: Remifentanil intravenous bolus dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: A remifentanil infusion was prepared as follows; 0.5 mg remifentanil was added into 100 mL of 0.9% saline at a concentration of 5 μg/mL. The preparation of remifentanil solution and installation of the device was done by an anesthesiologist who was blinded for the study groups. The dose and number of patients that required remifentanil were recorded. The infusion of drugs was discontinued at the end of the procedure. A rescue medication of intravenous remifentanil bolus dose was used as 1 to 3 mL (5 μg or 15 μg) every 5 minutes if necessary for pain scores greater than 3. This infusion was prepared prior to the use during the study and was discontinued at the end of the procedure.
Study: NCT02494024
Drug: Single dose C2N-8E12
Approvals — FDA: no, EMA: no, PMDA: no
Description: C2N-8E12 is a humanized recombinant anti-human tau antibody.
Study: NCT02494024
Drug: Single dose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be block randomized to receive a single dose of C2N-8E12 or placebo in two blocks of 4 subjects (3:1, C2N-8E12:placebo) per cohort.
Study: NCT00537836
Drug: BAY 86-5310 (ZK 283197)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg (3 x 1 mg tablet) or 2 mg (2 x 1 mg tablet) ZK 283197 in respective treatment group, once daily p.o. over 8 weeks
Study: NCT00537836
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once daily p.o. over 8 weeks
Study: NCT00537836
Drug: 17ß-estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg (2 x 0.5 mg tablet) 17ß-estradiol, once daily p.o. over 8 weeks
Study: NCT04089982
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01674530
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mcg capsules of both experimental Lubiprostone and AMITIZA
Study: NCT01137786
Drug: Non ionic contrast media comparator
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time administration for PCI
Study: NCT01137786
Drug: Non ionic contrast media comparator
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: one time administration for PCI
Study: NCT00147238
Drug: Ferumoxtran-10 (USPIO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 2.6 mg/kg of ferumoxtran-10
Study: NCT03697590
Drug: No curettage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PDT without curettage
Study: NCT03697590
Drug: Curettage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PDT
Study: NCT02412657
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00088855
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03719664
Drug: 3BNC117
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 3BNC117
Study: NCT00547495
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet taken by mouth, as needed, no more than 1 dose per day, for 12 weeks
Study: NCT03093506
Drug: Micro-dose rhEpo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20IU/kg/week
Study: NCT01052116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03719664
Drug: Baseline ART
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects continuing on baseline ART
Study: NCT00063622
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily
Study: NCT02026297
Drug: Placebo; Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Normal Saline
Study: NCT01582451
Drug: LY2605541
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01200641
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups).
Study: NCT01200641
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups).
Study: NCT00844675
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group will receive a placebo by mouth twice a day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
Study: NCT00101582
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02528396
Drug: Humalog®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection at t0,or t+15 minutes or t-15minutes with test meal
Study: NCT02962388
Drug: IFNα/ PegIFNα
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNα/ PegIFNα in the study, according to the investigator decision fom day 1 to 48 months
Study: NCT01206348
Drug: Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solodyn 1 tablet, Q day Ziana Gel, topical Q am Triaz FC, topical Q night
Study: NCT01146834
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.0 g/m2 (day 4 for Arm A and day 1 for Arm C)
Study: NCT00424203
Drug: AC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00424203
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00424203
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01919190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01739790
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo manufactured to mimic appearance of intervention drug with identical frequency and duration.
Study: NCT02240407
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: We will provide 650 mg of tylenol before each dose of Rituximab.
Study: NCT02240407
Drug: LMX 4 Topical Cream
Normalized name: LMX 4 Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia cream will be used prior to gene therapy/saline injection.
Study: NCT00175357
Drug: Diamorphine hydrochloride
Normalized name: Diamorphine hydrochloride
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of the drug will be determined by a physician. The injected drug will be administered up to 3 doses per day, 7 days per week.
Study: NCT01941095
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants may receive azathioprine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
Study: NCT00870142
Drug: Norvasc® 10 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fasting conditions
Study: NCT02232347
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01941095
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants may receive methotrexate as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
Study: NCT01456481
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The target dose in this study is 10mg q4h x3 for 12 months. The starting dose is 5mg q4h x3, and if tolerated a forced titration up to 10mg/dose. If there is an intolerance, then the dose can be reduced to 2.5mg/dose.
Study: NCT02196831
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactive substance that looks like tesamorelin
Study: NCT02646163
Drug: REP 2055
Approvals — FDA: no, EMA: no, PMDA: no
Description: (First two patients) REP 2055 is administered once weekly by slow IV infusion in dose escalation from 100 to 1200mg until a grade 3 adverse event is observed not to exceed 40 weeks of dosing.~(Subsequent patients) 400mg of REP 2055 is administered by slow IV infusion. First week of infusion to include daily dosing followed by twice weekly dosing for 40 weeks.
Study: NCT00149643
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gelatin capsules Fluoxetine 10 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of fluoxetine 20 mg, 2 capsules barring side effects.
Study: NCT01979900
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well，once every 2 weeks, 6 times totally.
Study: NCT03864978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02508389
Drug: Low Dose GC4419: 30mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
Study: NCT02508389
Drug: High Dose GC4419: 90mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
Study: NCT02508389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
Study: NCT02933606
Drug: BNC210
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02933606
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03241875
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this group, no premedication is performed, but patients receive 2 capsules of placebo 2 hours before anesthetic induction.
Study: NCT02964975
Drug: Optimal medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical threatment according to guidelines
Study: NCT01385033
Drug: [18F]MK-3328
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328
Study: NCT04153604
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a tetracycline antibiotic that fights bacteria in the body.
Study: NCT02906709
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to omarigliptin orally once weekly
Study: NCT01860976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02715869
Drug: A pharmacologic cardiac preconditioning (Sevoflurane)
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Patients are anaesthetized by Sevoflurane more than 1 mac.
Study: NCT03763175
Drug: SYN-010 21 mg
Normalized name: Gel-Syn
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
Study: NCT03763175
Drug: SYN-010 42 mg
Normalized name: Gel-Syn
Approvals — FDA: no, EMA: no, PMDA: no
Description: 42 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
Study: NCT03763175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
Study: NCT02392910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: At each visit, the patient lay on a stretcher and underwent a vein cannulation in the forearm with a commercial canula no. 16, which was connected to IV tubing that was connected to a bag of isotonic saline solution 0.9% (200 ml). Each infusion was administered throughout 60 min. This scheme was followed for 5 consecutive weeks.
Study: NCT00844519
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For subjects assigned to the placebo group, they will receive a matching placebo pill 300mg to be taken by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications.
Study: NCT00226655
Drug: hCRF [XERECEPT (corticorelin acetate injection)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg/day
Study: NCT02752477
Drug: Opioid-free general anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: An opioid-free general anesthetic technique utilizing dexmedetomidine, ketamine, and lidocaine infusions
Study: NCT02752477
Drug: Traditional general anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional general anesthetic technique utilizing sufentanil, fentanyl or remifentanil
Study: NCT01568541
Drug: Regular toothpastes
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tooth brushing
Study: NCT01568541
Drug: Children's toothpastes
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tooth brushing
Study: NCT02178956
Drug: BBI608
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBI608 480 mg orally two times daily (960 mg total daily dose)
Study: NCT00434486
Drug: SKI-606
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03129646
Drug: Paromomycin
Normalized name: Paromomycin
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paromomycin sulfate equiv to 750mg paromomycin / 2ml amp
Study: NCT01759914
Drug: Superpotent topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02802228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo delivered as infusion and oral capsule
Study: NCT02863575
Drug: Ibuprofen/Caffeine
Normalized name: Ibuprofen/Caffeine/Vitamins B1, B2, B6, & B12 400 mg-65 mg-25 mg-6.25 mg-25 mg-125 mcg ORAL COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen/Caffeine fixed-dose combination
Study: NCT02863575
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen capsule
Study: NCT02863575
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment
Study: NCT02972398
Drug: placebo comparator of N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants of placebo group receive placebo comparator matching with N-acetylcysteine twice daily for 12 weeks.
Study: NCT00006106
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006106
Drug: ONYX-015
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00634972
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00720096
Drug: Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal Doxorubicin 40 mg/m2 q 28 days
Study: NCT03814343
Drug: 30% DMSO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% DMSO was given to patients in placebo comparators group for continuous 12 weeks.
Study: NCT02358681
Drug: Ketorolac, intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route.